CRSP News and Press, CRISPR Therapeutics AG From 12/04/23

2023-12-04 05:00:00 ET CRISPR Therapeutics ' (NASDAQ: CRSP) stock has soared this year -- and for good reason. The biotech company is getting closer and closer to a major milestone: potential regulatory approval of what may become its first product. In just a few days, the U.S. Food...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-12-01 14:45:50 ET Summary AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovation. AI is turbocharging techniques like CRISPR and...

2023-12-01 05:15:00 ET With the markets rallying, right now is the perfect time to think about stocks that could offer your portfolio a good deal of growth. These players may not soar overnight, but thanks to their innovative technologies, they could become future winners -- and significant...

2023-11-30 14:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-30 04:36:44 ET Summary Beam Therapeutics focuses on base editing technology, which allows for precise changes at the DNA level and potentially reduces off-target effects. Base editing has the versatility to correct a wide range of point mutations, making it applicable to m...

2023-11-29 00:20:22 ET Summary Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline targeting various genetic diseases and conditions. ...

2023-11-27 16:30:28 ET Summary CRISPR Therapeutics has outperformed the S&P 500 significantly since my September update, as investors joined the bandwagon anticipating its commercial approval. The company received approval for its gene-editing therapy in the UK. Similarly, the...

2023-11-27 08:00:00 ET Summary MaxCyte is a pick-and-shovel play on cell editing technology, but may capture a royalty stream from successful products. Vertex's potential candidate approval in the U.S. could prove a decisive catalyst ultimately validating MaxCyte's approach and bu...

2023-11-25 03:39:49 ET Summary Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for its simplicity and versatility. Major publicly ...